Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 vs 7+3 in Untreated AML (60-75 Years)
NCT00788892Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2008
- Primary completion
- Jun 2010
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 2
01
Overview
A Phase 2 trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML), sponsored by Jazz Pharmaceuticals plc. Started Oct 2008; status: completed.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00788892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00788892.